Knight Therapeutics: A Record Quarter, a Raised Guide — and Two Honest Shadows

Revenues jump 68% to a record $148M and EBITDA soars 130%, yet management's candor on the Qelbree withdrawal and the fragility of the Ambisome MOH contract keeps the celebration measured.

GUD.TO · Earnings Call · 2026-05-07

A Record Quarter, and a Guide Raised Again

Knight Therapeutics entered 2026 in full stride. For the first quarter the company reported record revenues of $148 million — up 68% year over year — and record adjusted EBITDA of $28 million, up 130%. Adjusted EBITDA per share climbed 133% to $0.28, an expansion rate that far outstripped the 44% increase in operating expenses. Management credited the step change to incremental contributions from the Sumitomo and Paladin portfolios, the growth of strategic products such as Cresemba and Akynzeo, and purchasing patterns of certain customers. The strength allowed management to raise the fiscal 2026 outlook for the second consecutive period: revenues now guided to $510–525 million with adjusted EBITDA of approximately 15% of revenues. Samira Sakhia was explicit about what drove the beat vs. plan: “It's adding about $5 million to $10 million of that increase in the range. The rest is all coming from products.” — Samira Sakhia, President and CEO · 2026-05-07 In other words, only a small slice of the upgrade is FX — the engine is the underlying portfolio.

The Launch Engine Grinds On

The quarter's growth is not acquisition math alone. Management highlighted 15 launches executed over the past two years, four more already in 2026 — Minjuvi for follicular lymphoma in Brazil, Pemazyre in Argentina, Akynzeo in Paraguay, and Bapocil in Colombia — with roughly ten expected for the full year. In Q&A Samira framed the cadence as compounding incremental revenue across markets: “every single time we have a launch, it's incremental revenues that we would not have otherwise.” — Samira Sakhia, President and CEO · 2026-05-07 The pipeline's $200 million peak potential is already 20% realized, with $40 million of trailing twelve-month revenue from the 2024–26 cohort. The regulatory momentum around Minjuvi is notable: Brazilian approval for its second indication (follicular lymphoma) landed in the quarter, with submissions now live in Argentina and Mexico. Each country approval triggers its own launch event — physician education, reimbursement, market-building — a deliberate compounding model that contrasts with the prior quarter's emphasis on Jornay PM and the Canadian buildout.

Two Shadows: Qelbree and Ambisome

Despite the strength, two items temper the narrative. First is the withdrawal of the Health Canada new drug submission for Qelbree, driven by manufacturing changes by the manufacturing partner. Rather than answer regulator questions and address the changes piecemeal — which would delay the launch anyway — management chose to withdraw, compile all required data plus the previously requested technical information, and resubmit a "substantial dossier," accepting a one-to-two-year delay. Samira was candid:

It's better for us to withdraw the dossier, have all these manufacturing changes as well as the technical information that was previously requested, all done at the same time, have a dossier that we can submit and launch all in one shot.
Samira Sakhia, President and CEO · 2026-05-07

The second shadow is the Brazilian Ministry of Health contract for AmBisome — the single largest driver of the quarter's growth, contributing roughly $14 million incrementally. The annual order was revised upward from ~$32 million to ~$46 million, with the balance expected in Q2. But Samira was refreshingly blunt about its fragility: generics are under review in Brazil, and the contract exists only because the branded competitor has been unable to return to market after its back-order. “until they're approved, MOH has no other source of amphotericin B other than this.” — Samira Sakhia, President and CEO · 2026-05-07 The concentration risk is real — and management openly acknowledged that the Ambisome sales will almost certainly normalize once generics clear. This is a recurring theme from prior calls, where MOH orders were already flagged as volatile; in Q3 2025, management noted “we don't really have a commitment from them to purchase” — Samira Sakhia, President and CEO · 2025-08-08 beyond the initial order, underscoring the lumpiness.

Balance Sheet Firepower

The quarter also marked a balance-sheet inflection. Net cash improved from $27 million at year-end to $69 million, with $40 million of the $60 million credit facility draw already repaid and leverage under 0.7x adjusted EBITDA. The NCIB continued, with 1.3 million shares repurchased at an average of $6.22. In the context of last year's debt-funded Paladin acquisition — which drew analyst scrutiny on balance-sheet capacity — management now has both cash and undrawn borrowing capacity to keep executing its in-licensing and acquisition playbook. Amal Khouri described the BD pipeline as "very healthy," with an average of roughly three products added per year, excluding last year's two portfolio deals. Prior calls frame the trajectory: one year ago the concern was SG&A build-out and launch-investment drag on margins. Samira then framed profitability timing by noting “you don't really hit profitability until the third year” — Samira Sakhia, President and CEO · 2025-03-20 — and that infrastructure would become "rightsized." This quarter's 48% gross margin and the guided 15% EBITDA margin show that equation improving far faster than expected. The open question is the durability of organic growth once Ambisome's MOH contract normalizes — and whether LatAm generics erode brands as slowly as management has argued, particularly for Lenvima in Brazil and Colombia. Bottom line: a genuinely strong quarter with a raised guide, and management deserves credit for flagging the Qelbree setback and the Ambisome concentration risk in the same breath. The record results validate the Pan-American in-licensing model; the shadows keep the risk-reward honest.